ERS Genomics–Arciero M: management, 202009– VP IP + Commercial Development before USC Stevents Center for Innovation

	Period	2020-09-22
	Organisation	ERS Genomics Ltd.
	Product	IP services
	Product 2	CRISPR gene editing technology
	Person	Arciero, Michael (ERS Genomics 202009– VP IP + Commercial Development before USC Stevents Center for Innovation)

ERS Genomics Ltd.. (9/22/20). "Press Release: ERS Genomics Appoints Michael Arciero as Vice-President of Intellectual Property & Commercial Development". Dublin.

ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Michael Arciero as Vice-President of Intellectual Property and Commercial Development. In the new role, Michael will oversee the intellectual property portfolio of the company and will become a core member of the Company's global business development team.

Michael has over 15 years of experience in corporate and academic transactions. Most recently he was Director of Technology Commercialization and New Ventures for the USC Stevens Center for Innovation. In this function he led the technology transfer and corporate alliance teams supporting innovation across all disciplines, stemming from over $900M in annual research expenditures. Michael was pivotal in the establishment of new ventures based on intellectual property originating at USC. He has a bachelor’s degree in Biology from the University of California, San Diego, and a Juris Doctorate from the University of San Diego School of Law.

“We are absolutely thrilled to have Michael joining ERS at this stage in our corporate development," said Eric Rhodes, CEO, ERS Genomics. "Michael brings a strong background not only in intellectual property matters, but also in structuring deals with a wide range of companies. He will be a key asset in our global expansion efforts, focused on widespread adoption and use of CRISPR/Cas9 across industries including life sciences, veterinary science, and industrial chemicals.”

“The CRISPR/Cas9 system has already led to important research breakthroughs and we've only scratched the surface of what is possible,” commented Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics. “I'm excited to join ERS and help advance the Company’s mission to increase global commercial access to this revolutionary technology.”

For additional information please visit www.ersgenomics.com

For high resolution images please contact Zyme Communications

Contacts

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

Record changed: 2020-11-20

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x200px

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)